肝脏硬度值及血清生化指标与非酒精性脂肪性肝炎的相关性分析

付懿铭; 纪冬; 邵清; 李忠斌; 王春艳; 陈松海; 陈国凤

doi:10.3969/j.issn.1001-5256.2020.11.015

肝脏硬度值及血清生化指标与非酒精性脂肪性肝炎的相关性分析

DOI: 10.3969/j.issn.1001-5256.2020.11.015

解放军总医院第五医学中心肝病医学部

基金项目:

解放军总医院医疗大数据与人工智能研发项目（2019MBD-024）；首都临床特色应用研究特色课题（Z181100001718034）；菊梅肝胆病防治能力建设专项基金重点项目（2018JM126030032018）；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 4432
- HTML全文浏览量: 23
- PDF下载量: 141
- 被引次数: 0
出版历程
- 收稿日期: 2020-04-29
- 出版日期: 2020-11-20

Association of liver stiffness measurement and serum biochemical parameters with nonalcoholic steatohepatitis

Department of liver Disease,Fifth Medical Center of Chinese PLA General Hospital

Research funding:

摘要

摘要:
目的评估肝脏硬度值（LSM）及血清生化指标与非酒精性脂肪肝性肝炎（NASH）肝脏脂肪变、肝脏炎症、肝纤维化的相关性。方法选择2007年1月-2018年12月入住解放军总医院第五医学中心的NASH患者520例,依据BMI（界值为28 kg/m2）分为肥胖组（n=151）和非肥胖组（n=369）。所有患者均接受肝组织病理学检查,肝活检前3 d内检测LSM,收集患者肝穿前的血清生化学指标及一般临床资料,计算血清学无创模型数据APRI、FIB-4。正态分布计量资料2组间比较采用t检验;非正态分布计量资料2组间比较采用两独立样本非参数Mann-Whitney U检验。计数资料2组间比较采用χ2检验。相关性分析采用Spearman秩相关分析。结果随着BMI水平升高,ALT、AST、LSM、肝脏脂肪衰减参数、脾长、APRI逐渐升高,差异均有统计学意义（P值均<0.05）。Spearman相关分析显示LSM、ALT、BMI、CAP与肝脂肪变性程度呈正相关(r值分别为0.263、0.327、0.184、0.452,P值均<0.05; LSM、ALT...
- 非酒精性脂肪性肝病 /
- 弹性成像技术 /
- 活组织检查,针吸
Abstract:
Objective To investigate the association of liver stiffness measurement( LSM) and serum biochemical parameters with hepatic steatosis,liver inflammation,and liver fibrosis in patients with nonalcoholic steatohepatitis( NASH). Methods A total of 520 patients with NASH who were treated in The Fifth Medical Center of Chinese PLA General Hospital from January 2007 to December 2018 were enrolled,and according to body mass index( BMI) with a cut-off value of 28 kg/m2,the patients were divided into obese group with 151 patients and non-obese group with 369 patients. All patients underwent liver biopsy,and LSM was measured within 3 days before biopsy. Serum biochemical parameters and general clinical data were collected before liver biopsy,and the noninvasive indices aspartate aminotransferase to platelet ratio index( APRI) and fibrosis-4( FIB-4) were calculated. The t-test was used for comparison of normally distributed continuous between groups,the nonparametric Mann-Whitney U test was used for comparison of non-normally distributed continuous between groups; the chi-square test was used for comparison of categorical data between groups. A Spearman rank correlation analysis was also performed. Results Alanine aminotransferase( ALT),aspartate aminotransferase,LSM,controlled attenuation parameter( CAP),spleen length,and APRI gradually increased with the increase in BMI( all P < 0. 05). The Spearman correlation analysis showed that LSM,ALT,BMI,and CAP were positively correlated with the degree of hepatic steatosis( r = 0. 263,0. 327,0. 184,and 0. 452,all P < 0. 05); LSM,ALT,and CAP were positively correlated with the degree of liver inflammation( r = 0. 357,0. 278,and 0. 121,all P < 0. 05); LSM,ALT,BMI,and CAP were positively correlated with the degree of liver fibrosis( r = 0. 500,0. 216,0. 248,and 0. 101,all P < 0. 05); age was negatively correlated with the degree of hepatic steatosis,liver inflammation,and liver fibrosis( r =-0. 344,-0. 129,and-0. 163,all P < 0. 05). Conclusion LSM,CAP,ALT,and age are significantly correlated with the degree of liver inflammation,liver fibrosis,and hepatic steatosis in NASH patients,and therefore,they can be used in noninvasive diagnostic and predictive models to access the severity of liver injury.
- non-alcoholic fatty liver disease /
- elasticity imaging techniques /
- biopsy,needle

HTML全文

参考文献(24)

[1] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.

[2] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association,Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:2006[J]. Mod Digest Interv,2007,12(4):266-268.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病诊疗指南(2006年2月修订)[J]．现代消化及介入诊疗，2007,12(4):266-268.

[3] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association,Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957.

[4] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84.

[5] VILAR-GOMEZ E,CALZADILLA-BERTOT L,WAI-SUN WONG V,et al. Fibrosis severity as a determinant of causespecific mortality in patients with advanced nonalcoholic fatty liver disease:A multi-national cohort study[J]. Gastroenterology,2018,155(2):443-457.

[6] BEDOSSA P,PATEL K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease[J].Gastroenterology,2016,150(8):1811-1822.

[7] WONG VW,ADAMS LA,de LEDINGHEN V,et al. Noninvasive biomarkers in NAFLD and NASH-current progress and future promise[J]. Nat Rev Gastroenterol Hepatol,2018,15(8):461-478.

[8] BRUNT EM,JANNEY CG,di BISCEGLIE AM,et al. Nonalcoholic steatohepatitis:A proposal for grading and staging the histological lesions[J]. Am J Gastroenterol,1999,94(9):2467-2474.

[9] KLEINER DE,BRUNT EM,van NATTA M,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology,2005,41(6):1313-1321.

[10] ADAMS LA,FELDSTEIN AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis[J]. J Dig Dis,2011,12(1):10-16.

[11] LEUNG JC,LOONG TC,WEI JL,et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J]. Hepatology,2017,65(1):54-64.

[12] WANG Y,WANG B,SHEN F,et al. Body mass index and risk of primary liver cancer:A meta-analysis of prospective studies[J]. Oncologist,2012,17(11):1461-1468.

[13] WONG VW,WONG GL,YEUNG JC,et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram:A prospective cohort study[J]. Hepatology,2016,63(3):754-763.

[14] POYNARD T,RATZIU V,CHARLOTTE F,et al. Diagnostic value of biochemical markers(Nash Test)for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease[J]. BMC Gastroenterol,2006,6:34.

[15] PALEKAR NA,NAUS R,LARSON SP,et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease[J]. Liver Int,2006,26(2):151-156.

[16] ULITSKY A,ANANTHAKRISHNAN AN,KOMOROWSKI R,et al. A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients[J]. Obes Surg,2010,20(6):685-691.

[17] FU YM,JI D,WANG CY,et al. SAT-284-Diagnostic performance of transient elastography on liver fibrosis of patients with non-alcoholic fat hepatitis[J]. J Hepatol,2019,70(1):e761.

[18] LIANG J,ZHONG BY,TANG Y,et al. Study on liver fibrosis examination in nonalcoholic fatty liver disease[J]. Chin Health Standard Manage,2017,8(17):110-113.(in Chinese)梁健，钟碧莹，汤茵，等．肝纤维化检测在非酒精性脂肪肝诊断中的应用研究[J]．中国卫生标准管理，2017,8(17):110-113.

[19] LENG XJ,YAN XB. Efficiency of FibroTouch in evaluating liver fibrosis degree in nonalcoholic fatty liver disease patients with different levels of body mass index[J]. J Clin Hepatol,2018,34(9):1891-1895.(in Chinese)冷雪君，颜学兵．FibroTouch对不同BMI水平非酒精性脂肪性肝病患者肝纤维化程度的评估比较[J]．临床肝胆病杂志，2018,34(9):1891-1895.

[20] FU YM,JI D,XIONG YR,et al. Diagnostic performance of liver stiffness measurement on liver fibrosis of patients with nonalcoholic steatohepatitis[J]. Med J Chin PLA,2019,44(8):671-675.(in Chinese)付懿铭，纪冬，熊艺茹，等．肝脏弹性检测对非酒精性脂肪性肝炎肝纤维化分期的诊断效能[J]．解放军医学杂志，2019,44(8):671-675.

[21] XIAO G,ZHU S,XIAO X,et al. Comparison of laboratory tests,ultrasound,or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease:A meta-analysis[J]. Hepatology,2017,66(5):1486-1501.

[22] SHEN F,ZHENG RD,MI YQ,et al. A multi-center clinical study of a novel controlled attenuation parameter for assessment of fatty liver[J]. Chin J Hepatol,2014,22(12):926-931.(in Chinese)沈峰，郑瑞丹，宓余强，等．受控衰减参数诊断脂肪肝的临界值初探:一项多中心临床研究[J]．中华肝脏病杂志，2014,22(12):926-931.

[23] SHEN F,XU ZJ,PAN Q,et al. Influencing factors and reproducibility of controlled attenuation parameters in the evaluation of fatty liver disease using FibroScan[J]. J Pract Hepatol,2013,16(1):59-62.(in Chinese)沈峰，徐正婕，潘勤，等．FibroScan实施受控衰减参数评价脂肪肝的影响因素及重复性分析[J]．实用肝脏病杂志，2013,16(1):59-62.

[24] YATSUJI S,HASHIMOTO E,TOBARI M,et al. Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis[J]. Hepatol Res,2007,37(12):1034-1043.

施引文献

资源附件(0)

访问统计